Hero Technologies Past Earnings Performance
Past criteria checks 0/6
Hero Technologies has been growing earnings at an average annual rate of 82.2%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 95.9% per year.
Key information
82.2%
Earnings growth rate
115.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -95.9% |
| Return on equity | -3,916.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Hero Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -2 | 2 | 0 |
| 30 Jun 23 | 0 | -1 | 1 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -3 | 1 | 0 |
| 30 Sep 21 | 0 | -6 | 4 | 0 |
| 30 Jun 21 | 0 | -9 | 6 | 0 |
| 31 Mar 21 | 0 | -9 | 6 | 0 |
| 31 Dec 20 | 0 | -6 | 6 | 0 |
| 31 Dec 19 | 0 | -13 | 0 | 0 |
| 31 Mar 16 | 0 | -2 | 0 | 0 |
| 31 Dec 15 | 0 | -2 | 0 | 0 |
| 30 Sep 15 | 0 | 1 | 0 | 0 |
| 30 Jun 15 | 0 | 1 | 0 | 0 |
| 31 Mar 15 | 0 | 1 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
| 30 Sep 14 | 0 | -1 | 0 | 0 |
| 30 Jun 14 | 0 | -1 | 0 | 0 |
| 31 Mar 14 | 0 | -1 | 0 | 0 |
| 31 Dec 13 | 0 | -1 | 0 | 0 |
Quality Earnings: HENC is currently unprofitable.
Growing Profit Margin: HENC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HENC is unprofitable, but has reduced losses over the past 5 years at a rate of 82.2% per year.
Accelerating Growth: Unable to compare HENC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HENC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: HENC has a negative Return on Equity (-3916.78%), as it is currently unprofitable.